Profil
John D.
Weinberg worked as the Head of Oncology Business Unit at Enzon Pharmaceuticals, Inc. from 2003 to 2005.
He was the SVP of Commercial Operations & Investor Relations at Veloxis Pharmaceuticals A from 2010 to 2012.
He also worked as the Head of Business Franchise at Novartis Pharmaceuticals Corp.
and as the Chief Medical Officer at 4D Pharma Plc.
In 2020, he became the Chief Medical Officer at Maat Pharma SA. Weinberg holds an MBA from INSEAD and a doctorate from the University of the Witwatersrand.
Anciens postes connus de John D. Weinberg
| Sociétés | Poste | Fin |
|---|---|---|
| MAAT PHARMA | Chief Tech/Sci/R&D Officer | 01/06/2022 |
| VELOXIS PHARMACEUTICALS A/S | Chief Operating Officer | 29/02/2016 |
| ENZON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2005 |
| 4D PHARMA PLC | Chief Tech/Sci/R&D Officer | - |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Formation de John D. Weinberg
| INSEAD | Masters Business Admin |
| University of the Witwatersrand | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ENZON PHARMACEUTICALS, INC. | Health Technology |
| 4D PHARMA PLC | Health Technology |
| MAAT PHARMA | Health Technology |
| Entreprise privées | 2 |
|---|---|
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
